menu
    • menu
    [{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SNK01","moa":"KIRS","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biotech \/ Not Applicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SNK01","moa":"KIRS","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biotech \/ Not Applicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Autologous Natural killer cells","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biotech \/ Not Applicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SNK01","moa":"KIRS","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biotech \/ Not Applicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SNK02","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biotech \/ Not Applicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Parkinson\u2019s Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"SNK01","moa":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"NKGen Biotech \/ Parkinson\u2019s Foundation","highestDevelopmentStatusID":"5","companyTruncated":"NKGen Biotech \/ Parkinson\u2019s Foundation"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Graf Acquisition Corp. IV","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"SNK01","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Graf Acquisition Corp. IV","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Graf Acquisition Corp. IV"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"SNK02","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biotech \/ Not Applicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Graf Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"SNK01","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Graf Acquisition Corp.","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Graf Acquisition Corp."},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"SNK01","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Not Applicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"SNK01","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Not Applicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"SNK01","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Not Applicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"SNK01","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Not Applicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"SNK01","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Undisclosed"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"SNK01","moa":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NKGen Biotech \/ Not Applicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"SNK01","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Not Applicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Troculeucel","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Not Applicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Troculeucel","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Troculeucel","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Troculeucel","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"NKGen Biotech \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by NKGen Biotech

    Menu

    NKGen Biotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            NKGen Biotech

                            U.S.A arrow
                            World ADC London
                            Not Confirmed

                            NKGen Biotech

                            U.S.A arrow
                            World ADC London
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Troculeucel

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NKGen Doses First Stroke Patient with Troculeucel Under FDA Compassionate Use

                            Details : SNK01 (troculeucel) is an autologous, non-genetically modified NK cell product that has enhanced cytotoxicity and activating receptor expression, being investigated for stroke.

                            Product Name : SNK01

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            March 03, 2025

                            Lead Product(s) : Troculeucel

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NKGen Biotech

                            U.S.A arrow
                            World ADC London
                            Not Confirmed

                            NKGen Biotech

                            U.S.A arrow
                            World ADC London
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Troculeucel

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NKGen Announces Administration of First Dose of Troculeucel to FD Patient Under FDA

                            Details : SNK01 (troculeucel) is an autologous, non-genetically modified NK cell product that has enhanced cytotoxicity and activating receptor expression, being investigated for frontotemporal dementia.

                            Product Name : SNK01

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 21, 2025

                            Lead Product(s) : Troculeucel

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            NKGen Biotech

                            U.S.A arrow
                            World ADC London
                            Not Confirmed

                            NKGen Biotech

                            U.S.A arrow
                            World ADC London
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Troculeucel

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NKGen Gets FDA Fast Track for Troculeucel in Moderate Alzheimer’s Disease

                            Details : SNK01(troculeucel) is an autologous, non-genetically modified NK cell product that has enhanced cytotoxicity and activating receptor expression, being investigated for moderate Alzheimer’s Disease.

                            Product Name : SNK01

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 12, 2025

                            Lead Product(s) : Troculeucel

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            NKGen Biotech

                            U.S.A arrow
                            World ADC London
                            Not Confirmed

                            NKGen Biotech

                            U.S.A arrow
                            World ADC London
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Troculeucel

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NKGen Biotech Advances Troculeucel into Phase 2 in Moderate Alzheimer’s Disease

                            Details : SNK01(troculeucel) is an autologous, non-genetically modified NK cell product that has enhanced cytotoxicity and activating receptor expression, being investigated for moderate Alzheimer’s Disease.

                            Product Name : SNK01

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 12, 2024

                            Lead Product(s) : Troculeucel

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            NKGen Biotech

                            U.S.A arrow
                            World ADC London
                            Not Confirmed

                            NKGen Biotech

                            U.S.A arrow
                            World ADC London
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNK01

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NKGen Biotech's SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in AD

                            Details : SNK01 is a first-in-kind, autologous non-genetically modified NK cell product with significant anti-tumor cytotoxicity. It is being evaluated for the treatment of Alzheimer’s disease.

                            Product Name : SNK01

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 20, 2024

                            Lead Product(s) : SNK01

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            NKGen Biotech

                            U.S.A arrow
                            World ADC London
                            Not Confirmed

                            NKGen Biotech

                            U.S.A arrow
                            World ADC London
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNK01

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NKGen Gets FDA Clearance for IND Application of SNK01 NK Cell Therapy in Parkinson's

                            Details : SNK01 is an autologous, non-genetically modified NK cell product that has enhanced cytotoxicity and activating receptor expression, which is being evaluated for moderate Parkinson’s Disease.

                            Product Name : SNK01

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            April 29, 2024

                            Lead Product(s) : SNK01

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            NKGen Biotech

                            U.S.A arrow
                            World ADC London
                            Not Confirmed

                            NKGen Biotech

                            U.S.A arrow
                            World ADC London
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNK01

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            NKGen Secures $5 Million in Additional Financing to Advance Clinical Programs

                            Details : The proceeds will be used to advance NKGen's SNK01, an autologous NK cell therapy candidate, for phase 2 alzheimer’s clinical trial and the company has recently submitted IND for parkinson’s disease.

                            Product Name : SNK01

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 11, 2024

                            Lead Product(s) : SNK01

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            NKGen Biotech

                            U.S.A arrow
                            World ADC London
                            Not Confirmed

                            NKGen Biotech

                            U.S.A arrow
                            World ADC London
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNK01

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NKGen Presents Additional Phase 1 Trial Data in Alzheimer's at Tau2024 Global Conference

                            Details : SNK01 is a first-in-kind, autologous non-genetically modified NK cell product with significant anti-tumor cytotoxicity. It is being evaluated for the treatment of Alzheimer’s disease.

                            Product Name : SNK01

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            March 25, 2024

                            Lead Product(s) : SNK01

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            NKGen Biotech

                            U.S.A arrow
                            World ADC London
                            Not Confirmed

                            NKGen Biotech

                            U.S.A arrow
                            World ADC London
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNK01

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product,...

                            Details : SNK01 is an autologous, non-genetically modified NK cell product that has enhanced cytotoxicity and activating receptor expression, which is being evaluated in phase 1/2 clinical trials for the treatment of moderate Alzheimer’s Disease.

                            Product Name : SNK01

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 28, 2023

                            Lead Product(s) : SNK01

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            NKGen Biotech

                            U.S.A arrow
                            World ADC London
                            Not Confirmed

                            NKGen Biotech

                            U.S.A arrow
                            World ADC London
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNK01

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to ...

                            Details : SNK01 is an autologous, non-genetically modified NK cell product that has enhanced cytotoxicity and activating receptor expression, which is being evaluated in phase 1/2 clinical trials for the treatment of moderate Alzheimer’s Disease.

                            Product Name : SNK01

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 27, 2023

                            Lead Product(s) : SNK01

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth